Zogenix, Inc. (NASDAQ:ZGNX) – William Blair issued their Q1 2021 earnings per share estimates for shares of Zogenix in a note issued to investors on Friday, June 26th. William Blair analyst T. Lugo anticipates that the company will earn ($0.85) per share for the quarter. William Blair has a “Buy” rating on the stock. William Blair also issued estimates for Zogenix’s Q2 2021 earnings at ($0.67) EPS, Q3 2021 earnings at ($2.99) EPS and Q4 2021 earnings at ($0.37) EPS.
Several other equities research analysts also recently commented on the company. Northland Securities began coverage on Zogenix in a report on Friday. They issued a “buy” rating and a $65.00 price objective for the company. BidaskClub cut Zogenix from a “hold” rating to a “sell” rating in a research report on Saturday, June 20th. ValuEngine cut Zogenix from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 9th. Mizuho dropped their target price on Zogenix from $64.00 to $55.00 in a research report on Monday. Finally, Citigroup began coverage on Zogenix in a research report on Thursday, March 5th. They issued a “neutral” rating and a $27.00 target price on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $54.36.
NASDAQ ZGNX opened at $26.11 on Monday. Zogenix has a one year low of $16.65 and a one year high of $57.22. The stock has a 50-day moving average of $28.76 and a 200 day moving average of $34.30. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -2.77 and a beta of 1.79. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.39 and a current ratio of 5.39.
Zogenix (NASDAQ:ZGNX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($1.08) by $0.54. Zogenix had a negative return on equity of 47.19% and a negative net margin of 8,374.54%. The firm had revenue of $1.25 million during the quarter, compared to the consensus estimate of $0.38 million. During the same period last year, the company earned ($0.83) earnings per share. The company’s revenue was up 124800.0% on a year-over-year basis.
A number of large investors have recently added to or reduced their stakes in the business. US Bancorp DE increased its position in shares of Zogenix by 2,196.6% during the 1st quarter. US Bancorp DE now owns 1,332 shares of the company’s stock valued at $32,000 after purchasing an additional 1,274 shares during the last quarter. Meeder Asset Management Inc. bought a new position in shares of Zogenix during the 4th quarter valued at approximately $66,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Zogenix by 63.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,691 shares of the company’s stock valued at $91,000 after purchasing an additional 1,432 shares during the last quarter. Exane Derivatives bought a new position in shares of Zogenix during the 1st quarter valued at approximately $108,000. Finally, Quantbot Technologies LP bought a new position in shares of Zogenix during the 4th quarter valued at approximately $118,000.
In other news, EVP Ashish M. Sagrolikar acquired 1,000 shares of Zogenix stock in a transaction on Friday, May 8th. The shares were acquired at an average price of $27.61 per share, with a total value of $27,610.00. Following the purchase, the executive vice president now directly owns 5,913 shares in the company, valued at approximately $163,257.93. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 3.50% of the stock is currently owned by company insiders.
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.
Featured Story: Why do earnings reports matter?
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.